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Abstract: The treatment of viral diseases remains an intractable problem facing the medical community. 
Conventional antivirals focus upon selective targeting of virus-encoded targets. However, the plasticity of viral 
nucleic acid mutation, coupled with the large number of progeny that can emerge from a single infected cells, 
often conspire to render conventional antivirals ineffective as resistant variants emerge.  Compounding this, new 
viral pathogens are increasingly recognized and it is highly improbable that conventional approaches could 
address emerging pathogens in a timely manner. Our laboratories have adopted an orthogonal approach to 
combat viral disease: Target the host to deny the pathogen the ability to cause disease. The advantages of this 
novel approach are many-fold, including the potential to identify host pathways that are applicable to a broad-
spectrum of pathogens. The acquisition of drug resistance might also be minimized since selective pressure is not 
directly placed upon the viral pathogen. Herein, we utilized this strategy of host-oriented therapeutics to screen 
small molecules for their abilities to block infection by multiple, unrelated virus types and identified FGI-104.  FGI-
104 demonstrates broad-spectrum inhibition of multiple blood-borne pathogens (HCV, HBV, HIV) as well as 
emerging biothreats (Ebola, VEE, Cowpox, PRRSV infection).  We also demonstrate that FGI-104 displays an ability 
to prevent lethality from Ebola in vivo. Altogether, these findings reinforce the concept of host-oriented 
therapeutics and present a much-needed opportunity to identify antiviral drugs that are broad-spectrum and 
durable in their application. 
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Introduction 
 
Effective treatment of viral diseases remains a 
primary obstacle confronting the medical 
community.  Following infection, viruses hijack 
the host cell machinery to facilitate their 
replication and dissemination.  As such, 
viruses have generally adapted to encode for a 
minimal number of genes. In an effort to 
minimize cross-reactivity with host molecules, 
conventional antivirals have been designed to 
target the relatively small number of virally-
encoded targets and mechanisms. Successful 
examples include therapeutic targeting of 
retroviral reverse transcriptase (in the case of 
retroviruses) or thymidine kinase (in the case 
of herpesviruses) [1, 2].  Unfortunately, 
conventional antivirals are often themselves 
toxic and more importantly, targeting of viral 
targets places direct selective pressure upon 
the virus to minimize the impact of the drug 
via random mutation of the target molecule [3, 
4].  Viral polymerases generally display poor 
fidelity and compounding this, emerging 
evidence indicates that antiviral therapy itself 
further selectively promotes the growth of 
mutant variants [5]. Consequently, antiviral 
therapeutics are often rendered ineffective 
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over time as resistant viruses become more 
prevalent within an infected community.  To 
counter this, combination therapies using 
multiple drugs have been successfully applied 
but as demonstrated by the situation with 
HAART therapy for HIV/AIDS, issues of 
fundamental biology combined with decreased 
compliance in asymptomatic individuals, has 
facilitated the emergence of variants that are 
resistant even to combination therapy [6]. 
These outcomes are not limited to HIV. 
Similarly, the recent emergence of H5N1 
influenza has reinforced the idea of rapid 
resistance since drug resistant strains of 
H5N1 rapidly became prominent in the 
months since the virus first emerged [7, 8]. 
 
The difficulty in treating infections is 
compounded further when the viral pathogen 
is emerging or unknown. The past few decades 
have witnessed many emerging pathogens, 
including Ebola, VEE, SARS and PRRS viruses 
[9-11]. Compounding these natural infections, 
viral pathogens may be manipulated in the 
laboratory to increase their pathogenicity or 
transmissibility and virus-based bioweapons 
are increasingly recognized as a potential 
threat.  These facts emphasize the need for 
new antivirals that can be used to treat both 
known and unknowable viral pathogens.  Such 
needs are seemingly inconsistent with 
conventional approaches to develop therapies 
based on virus-encoded targets since the 
targets themselves may not be identifiable. 
 
Host-directed therapeutics may provide a 
much-needed means of combating both 
established and emerging viral diseases. The 
fundamental concepts underlying host-
oriented therapeutics are well-established and 
grounded in a basic understanding of viral 
biology.  While minimizing the number of 
virally-encoded mechanisms, most viruses 
have developed means to exploit routine host-
encoded “housekeeping” molecules [12-14]. 
In doing so, however, the virus often alters the 
expression or function of these housekeeping 
molecules.  An example of this “hijacking” 
function is portrayed by events associated with 
TSG101 [15, 16].   
 
TSG101 is a housekeeping protein that 
normally functions to escort internalized 
proteins that have been fated for degradation 
within proteosomes [17-20].  As such, TSG101 
is restricted to the cell interior, where it resides 
in structures known as multivesicular bodies. 
Enveloped viruses encounter the opposite 
situation than that of internalized membrane 
proteins since they are assembled inside the 
cell but need to transit to and through the cell 
membrane [15, 16].  Consequently, many 
viruses have converged upon a mechanism by 
which the function of TSG101 is “hijacked” in 
a manner that facilitates a retrograde 
movement of viruses from the cell interior to 
the outer membrane [16]. Indeed, a well-
developed literature has demonstrated that 
TSG101 plays an essential role in the viral life 
cycle and that this role is independent of its 
normal role in proteosomal transport [21]. 
Moreover, this mechanism is shared by a 
surprisingly broad spectrum of different 
viruses encompassing families virtually from 
all subsets defined by the standard Baltimore 
classification system.  This remarkable 
utilization of a single mechanism presumably 
reflects a convergent evolution by different 
virus types towards a fundamental mechanism 
necessary for the viral life cycle.  Based on 
these findings, we sought to identify potential 
therapeutics that might target TSG101 and be 
broadly-relevant to unrelated virus types.  We 
demonstrated herein the identification of FGI-
104, a small molecule antiviral with broad-
spectrum applicability and unprecedented 
ability to prevent viral pathogenesis in vivo. 
 
Materials and Methods 
 
In vitro anti-HBV evaluation  
 
HepG2 2.2.15 cells were plated in 96-well 
microtiter plates.  Only the interior wells were 
utilized to reduce “edge effects” observed 
during cell culture; the exterior wells are filled 
with complete medium to help minimize 
sample evaporation.  After 16-24 hours the 
confluent monolayer of HepG2-2.2.15 cells 
was washed and the medium was replaced 
with complete medium containing six dilutions 
of the test compound in triplicate. Lamivudine 
(2', 3'-dideoxy-3'-thiacytidine) was used as the 
positive control, while media alone was added 
to cells as a negative control. Three days later 
the culture medium was replaced with fresh 
medium containing the appropriately diluted 
drug. Six days following the initial 
administration of the test compound, the cell 
culture supernatant and the cells were 
collected to measure copy number of 
intracellular and extracellular HBV DNA, 
respectively, in a real-time qPCR (TaqMan) 
assay. Antiviral activity was calculated from 
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the reduction in HBV DNA levels (IC50). 
Compound cytotoxicity (TC50) was assessed in 
parallel by measuring cell viability with Cell 
Titer 96 (Promega, Madison, WI). The 
therapeutic index (TI) is calculated as 
TC50/IC50. 
 
Evaluation of HCV  
 
The ET cell line harboring HCV subgenomic 
replicon was obtained from Dr. Ralf 
Bartenschlager at University of Heidelberger 
[22]. The HCV replicon assay evaluated 
compounds at six half-log concentrations 
each. Human interferon alpha-2b is included 
in each run as a positive control compound. 
Briefly, sub-confluent cultures of the ET line 
were plated out into 96-well plates that were 
dedicated for the analysis of cell numbers 
(cytotoxicity) or antiviral activity. On the 
following day, compounds were added to the 
appropriate wells. Cells were processed 72 hr 
later when the cells were still sub-confluent. 
HCV replicon-derived luciferase activity was 
measured to derive applicable IC50 and IC90 
(concentrations resulting in 50% and 90% 
inhibition, respectively). The cytotoxic effects 
were assessed using the CytoTox-1 cell 
proliferation assay (Promega) according to 
manufacture’s instructions.  
 
To evaluate release of infectious HCV 
particles, human hepatoma cells (Huh7) were 
infected with a recombinant hepatitis C virus 
(HCV) that expresses a renilla luciferase. At 2 
hours post-infection, HCV-infected cells were 
incubated with compounds at concentrations 
from 30 to 0.04 µM in a 3-fold serial dilution 
(30, 10, 3.33, 1.11, 0.37, 0.12, and 0.04 µM). 
At 3 days post-infection, cells were lysed in a 
buffer included in a Promega luciferase assay 
kit. The level of luciferase expression was 
determined by luciferase assay using a kit 
derived from Promega.  To evaluate reduction 
of HCV protein, Huh7 cells were infected with 
HCV. At 2 hours post-infection, HCV was 
removed and cells were washed once with 
PBS. HCV-infected cells were then incubated 
with inhibitors at indicated concentrations at 
37oC for three days. Cell lysate was prepared 
by extracting cells in 50 µl RIPA buffer. The 
level of HCV NS5A protein was determined by 
Western blot analysis using an NS5A-specific 
monoclonal antibody.  
 
In vitro testing of HIV 
 
MT4 cells were infected with HIV-1 NL4–3 at 
MOI of 0.001 by low speed centrifugation 
(1,200g) for 1hr. Cells were seeded in a 96-
well plate (1.5x10^5 in 100ul culture medium 
per well)[23]. Serial dilution of FGI-104 was 
immediately added in triplicate in 50ul culture 
medium per well. †Half of the supernatants 
were refreshed every day starting from day 3 
pi in the presence of same concentration of 
FGI-104. The collected supernatants were 
then transferred to the TZM-bl indicator cell 
line (reference below) for examination of viral 
production in FGI-104 treated samples. 
Relative Luminescence Unit (RLU) was 
obtained on TZM-bl cells after they were 
treated with Bright-Glo Luciferase Assay 
System (Promega) 3 days later. The 
percentages of inhibition of viral production by 
FGI-104 were calculated as: (RLU from mock-
treated samples - RLU from FGI-104 treated 
samples)/RLU from mock-treated samples 
*100. Normal MT4 cells were treated with 
serial dilution of FGI-104 as same as above 
and its cytotoxicity was measured by 
CytoTox96 Non-Radioactive Cytotoxicity Assay 
(Promega) according to the manufacturer’s 
instruction. 
 
In vitro testing of PRRS virus  
 
The fluorescent focus inhibition assays were 
performed as previously described with minor 
modifications [24]. Anti-viral compounds were 
diluted in Eagle’s Minimum Essential Medium 
(MEM) containing 2% horse serum. 100ul of 
selected dilutions were added to duplicate 
wells of 96-well tissue culture plates and an 
equal volume of the selected PRRSV isolate 
(North American Type 2 strain SD-23983 or 
European-like Type 1 strain SD 01-08) at 2000 
TCID50/mL was then added to each well. The 
contents of each plate were then transferred 
to corresponding wells of another 96-well plate 
containing confluent monolayers of MARC-145 
cells or primary porcine macrophages set 48 
hrs prior to infection. Plates were incubated for 
24 hrs at 37C, then fixed with 80% acetone in 
water and stained with fluorescein-conjugated 
anti-PRRSV monoclonal antibody SDOW-17 
[25]. Endpoints were interpreted as the 
greatest dilution of anti-viral compound 
resulting in a 90% or 100% reduction in 
fluorescent foci of virus infected cells relative 
to control wells. All assays were conducted 
with a 2 hr pre-incubation of cells with the 
compound and with the compounds being 
added at the same time as the virus and no 
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differences in endpoints were noted. 
 
Plaque reduction assays were performed as 
previously described [26] with the following 
modifications. Selected anti-viral dilutions 
were mixed with input viruses at an M.O.I. of 
0.1. Results were interpreted as a percentage 
reduction in visible plaques relative to control 
wells receiving no anti-viral compound. 
 
In Vitro testing against Ebola virus  
 
Ebola Virus expressing the eGFP was derived 
by reverse genetics to generate a full-length 
cDNA clone inserted with a foreign reporter 
gene, eGFP (EboZ-eGFP). Generation of EboZ-
eGFP, showed similar viral characteristics to 
the wild-type virus yet causes infected cell to 
fluoresce green when stimulated.  EboZ-eGFP 
has provided a more sensitive quantitative 
assay to rapidly screen multiple drugs in less 
time [27].  
 
Vero E6 cells were seeded at 40,000 
cells/well in 96-black well plates and 
incubated at 37C with 5% CO2 with EMEM 
provided by (Invitrogen) complete with 10% 
FBS + 5% L-Glutamine and Hepes buffer 
(EMEM-C). Primary drug plates were received 
from Functional Genetics Inc. packaged on dry 
ice containing 25µl of 1mM compounds of 
interest. Dilution plates were generated by 
transferring 20µl of each compound from the 
primary drug plate to 80µl of EMEM and 
mixing for a final dilution of 50.00µm. Further 
dilution of each compound by transferring 33µl 
of the previous concentration into 66µl of 
EMEM and repeating three more times, 
created a range of concentrations to assess at 
which dose viral inhibition or cell toxicity is 
greatest. The final concentration range was 
50.00µm, 16.5µm, 5.56µm, 1.85µm, and 
0.62µm. After 24hour incubation of seeded 
cells and proper dilution of the compounds, 
25µl from the dilution plate was transferred to 
two cell plates; one cell plate would be used 
for the EboZ-eGFP infection and the second for 
the Cell Cytotoxicity assay described below. 
The plates used for the EboZ-eGFP infection 
were transferred into Bio-Safety Level-4 
containment (BSL-4), whereas, those used for 
the Cell Cytotoxicity assay remained at Bio-
Safety Level-2 containment until the 72 hour 
time point. At BSL-4, 25µl of EboZ-eGFP virus 
diluted in EMEM at 1:16 was added to each 
infection plate, with an additional 50µl EMEM-
C afterwards.  Infected EboZ-eGFP assay 
plates incubate for 72 hours at 37C with 5% 
CO2; after incubation, plates are read for 
fluorescence on a Gemini EM provided by 
Molecular Devices.  At the same time, plates 
remaining in BSL-2 are used for the below 
described Cell Cytotoxicity assay.  
 
CellTiter-Glo Luminescent Cell Viability Assay 
provided by Promega is a method of 
determining the number of viable cells based 
on the quantitation of the ATP present, which 
signals the presence of metabolically active 
cells (Promega).  CellTiter-Glo Buffer and 
lyophilized CellTiter-Glo substrate are removed 
from -20C storage into -4C for thawing 24 
hours before use. After proper thawing and 
equilibration to room temperature the 
CellTiter-Glo buffer is added to the substrate 
and mixed by inverting the closed bottle, 
making the CellTiter-Glo Reagent mixture.  All 
media and compound concentrations added to 
the assay plate, as described below, are 
discarded by flicking into a waste container of 
MicroChem disinfectant after 72 hour 
incubation with compounds. CellTiter-Glo 
reagent mixture and DMEM (Invitrogen) are 
added in equal amounts 1:1 for a final volume 
of 200µl/well. After addition of the reagent 
and media, the samples were mixed using an 
orbital shaker for two minutes; after mixing, 
plates incubate at room temperature for 10 
minutes to stabilize the luminescence signal. 
Plates are then read for luminescence on the 
Safire2 provided by Tecan.  
 
In Vivo testing in lethal mouse model of Ebola 
challenge   
 
Mouse-adapted Ebola virus was derived by 
serial passage of Ebola Zaire ‘76 in suckling 
mice; virus was obtained from Dr. Mike Bray 
[28]. Female C57BL/6 mice (4-8 weeks of 
age) were obtained from the Animal 
Production Area at the National Cancer 
Institute (Frederick, MD) and housed in sterile 
cages with sterile food and water. All research 
was conducted in accordance with the Animal 
Welfare Act and the principles stated in the 
Guide for the Care and Use of Laboratory 
Animals in an AAALAC accredited facility.  
During infection, mice were transferred to a 
Bio-Safety Level-4 containment area. Mice 
were treated with FGI-104 (10mg/kg) by 
200.0µl I.P. injection then exposed to 1000 
PFU of mouse-adapted Ebola virus by 200.0 µL 
I.P. injection two hours after the initial 
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treatment. Every 24 hours, for ten continuous 
days, mice received a single dose of FGI-104 
and were observed daily for morbidity, weights 
and mortality for a minimum of 3 weeks. 
Under Bio-Safety Level-4 conditions, all 
laboratory personnel wore positive-pressure 
protective suits (ILC Dover, Frederica, DE) 
fitted with HEPA filters and umbilical-fed air.  
 
Results 
 
Cell-based assays to identify inhibitors of 
blood-borne pathogens 
 
A focus library of small molecule compounds 
was tested for their abilities to block viral 
replication. These compounds were selected in 
part based on presumed capacity to block the 
interaction of TSG101 with its viral cognate 
ligands as determined using computational 
algorithms. The emphasis upon TSG101 was 
based on investigation from our laboratory and 
others, which demonstrate the host-derived 
TSG101 provides an opportunity to target 
multiple and different families of viruses that 
converge upon a common host pathway for 
viral budding and release [16]. 
 
To identify compounds with broad-spectrum 
activity against multiple virus types, a series of 
cell-based assays were utilized.  The viruses 
selected for the initial screen were broadly 
divided into two groups.  One group consisted 
of HIV, Hepatitis B virus (HBV) and Hepatitis C 
virus (HCV). These particular viruses were 
selected since they are often co-morbid within 
the same affected individuals [29]. A second 
group consisted of Ebola, Cowpox, Porcine 
Respiratory and Reproductive Syndrome virus 
(PRRS) and Venezuelan Equine Encephalitis 
(VEE) viruses. The latter group was 
emphasized since each represents an 
emerging virus and/or biothreat agent. 
Altogether, the pathogens under investigation 
comprised a broad array of unrelated virus 
families, which vary with regards when 
comparing the type of genomic nucleic acid, its 
strandedness and methods of replication 
(Table 1). 
 
Cell-based assays identified one particular 
compound with potent activity against multiple 
virus types. One series of studies sought to 
determine the ability of the compounds to 
inhibit HCV infection of host cells. A luciferase-
based infection of Huh7 cells with HCVcc 
(clone JFH-1) was employed. This particular 
model was selected since most other assay 
systems for HCV assess the number of 
replicons [22], which is problematic since 
TSG101 functions in viral budding and release 
and thus is downstream of nucleic acid 
replication. Using this system, one particular 
compound, known hereafter as FGI-104, 
demonstrated potent inhibition of HCV release.  
FGI-104 decreased HCV-based luciferase 
activity in a dose-dependent manner and 
achieved 99.5% relative to untreated controls 
at a concentration of 5 M (Figure 1A). The 
potency of FGI-104 was also indicated by its 
relatively low EC50 of 280 nM. Cytotoxicity of 
the compound was assessed in parallel and no 
significant cytotoxic effects of FGI-104 were 
observed at the test concentration range (data 
not shown). Moreover, the levels of HCV-
derived NS5A, a non-structural protein 
encoded by HCV, were assessed by Western 
blot analysis (Figure 1B). Parallel assessments 
of -actin levels provided a matched control 
for sample loading. Western blot analysis of 
NS5A confirmed the dose-dependent inhibition 
of HCV by FGI-104.  
Table 1. Broad spectrum antiviral activity of FGI-104 
Virus Type Genome Type EC50 (µM) CC50 (µM) SI 
HCV Flavivirus (+) sense RNA 0.28 20 uM 71 
HBV Hepadnavirus dsDNA-RT 0.02 14 700 
PRRS Arterivirus (+) ssRNA 0.3 >50 >150 
Cowpox Poxvirus dsDNA 0.25 >25 >100 
Ebola Filovirus (-) ssRNA 10 >50 >5 
VEE Togavirus (+) ssRNA 2.5 >25 >10 
HIV Retrovirus ssRNA-RT 8 43 5 
Shown is a summary of FGI-104 antiviral activity using cell-based assays.  Please note that SI represents a 
relative “safety index,” defined as the CC50/EC50. 
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Promising findings with HCV led us to evaluate 
the potential of FGI-104 to inhibit other virus 
types. We first evaluated those virus types, 
which are often co-morbid with HCV.  Cell-
based assays of HBV and HIV demonstrated 
consistent inhibition of each virus type in cell-
based assays. For example, FGI-104 inhibited 
HBV infection of HepG2 cells and in a dose-
dependent manner, with an estimated EC50 of 
20 nM (Figure 2A).  Similar to the results with 
Huh7 cells, the levels of FGI-104 associated 
with antiviral activity were considerably lower 
than levels associated with toxicity (with the 
CC50 estimated at 14 M, 700-fold higher 
than the EC50; Figure 2B).  Similar studies 
found FGI-104 also decreased HIV infection of 
MT-4 cells, albeit at higher levels of drug than 
were required for HBV or HCV (with an 
estimated EC50 of 8.5 M). 
 
In the course of evaluating FGI-104 antiviral 
activity, we investigated further the 
mechanistic basis of antiviral activity, with 
emphasis upon its impact on the viral life 
cycle. Based on the potential link with TSG101 
we reasoned that FGI-104 would likely impact 
a point in the viral life cycle after nucleic acid 
replication but prior to viral budding and 
release.  To test this hypothesis, the 
compound was further evaluated with the HCV 
subgenomic replicon. No appreciable activity 
was observed against the replicon system, 
suggesting that FGI-104 has no inhibitory 
effects on HCV replication (Figure 3A, B). The 
compound was further evaluated for anti-HBV 
activity by measuring either intracellular or 
extracellular HBV DNA copy number. Whereas 
FGI-104 demonstrated potent inhibition of 
extracellular HBV and virus release, it had no 
effects on the intracellular accumulation of 
HBV DNA, or virus replication (Figure 3D). 
These findings are therefore consistent with 
the idea that FGI-104 blocks a stage of the 
viral life cycle prior to budding and release but 
after nucleic acid replication. 
 
Figure 1. FGI-104 inhibition of HCV in cell-based 
assays.  Huh7 cells  were infected with luciferase 
expressing HCV JFH-1 virus for 72 hours in the 
presence of absence of FGI-104, with vehicle 
treated samples providing a negative control.  (A) 
Luciferase-based readouts of viral release into the 
culture supernatant demonstrated dose-dependent 
inhibition of HCV replication by FGI-104. (B) The 
expression levels of virally-encoded NS5A as 
measured by western blot analysis provided an 
independent confirmation of dose-dependent 
inhibition of HCV by FGI-104. 
 
Figure 2. FGI-104 inhibition of HBV. HepG2 cells 
expressing  HBV replicons was treated for 72 hours 
in the presence or absence of FGI-104, with vehicle 
treated samples providing a negative control.  (A) 
The number of HBV genomic copies in the culture 
supernatant was assessed by using quantitative 
PCR ,, demonstrating a dose-dependent inhibition 
of viral release. (B) The impact of FGI-104 
treatment on overall cell survival and metabolism 
was assessed to preclude the potential that the 
observed antiviral activity simply reflected an 
overall decrease in host cell metabolic activity. 
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Broad spectrum inhibition of emerging and 
biothreat agents   
 
We then compared the work using established 
viruses (HCV, HBV and HIV) with emerging 
virus types to test the concept of application of 
TSG101 both to known and unknowable viral 
pathogens.  As an example, a series of studies 
were conducted using PRRS virus. This 
particular pathogen was selected since it was 
first reported in 1987 and based on the far-
reaching economic impact of PRRS as 
evidenced by the catastrophic ongoing 
outbreak in China [30, 31].  Cell-based assays 
of PRRS demonstrated potent antiviral activity. 
For example, FGI-104 treatment of Marc-145 
cells could completely inhibit PRRS 
propagation as indicated using plaque 
formation assays (Figure 4A), with an 
estimated EC90 of 1.6 M (Figure 4B).  
Importantly, the potent activity against PRRS 
was comparably observed using both major 
strains of the virus (European and North 
American isolates; data not shown). We further 
demonstrated that the antiviral activity was 
not unique to any particular model system 
since comparable inhibition of PRRS virus was 
documented using either primary porcine-
derived macrophages or the Marc-145 cell 
model as the host target for infection.  The 
potential breadth of FGI-104 application was 
demonstrated by inhibition of other emerging 
or biothreat agents (Table 1). For example, 
FGI-104 demonstrated a dose-dependent 
inhibition of the propagation of additional 
viruses, including Cowpox, VEE and Ebola 
viruses (Figure 5 and data not shown). 
However, FGI-104 was not able to inhibit a 
number of other virus types including multiple 
and different seasonal variants of influenza 
(data not shown). Notably, multiple and 
different assay systems were utilized (e.g., 
viral titer or assessment of viral killing of host 
cells) to evaluate these viruses and FGI-104 
demonstrated consistent abilities to inhibit 
viral infection regardless of the experimental 
Figure 3. The mechanistic basis of FGI-104 antiviral activity occurs after nucleic acid replication. The antiviral 
activity of FGI-104 was assessed using standard replicon assays of nucleic acid replication for HCV (A,B) and 
HBV (C). Note that the data compiled in (B) and (C) represents summaries of multiple experiments. Unlike the 
potent inhibition observed previously with assay systems that measured release of infectious virions, 
assessments of intracellular nucleic acid replication did not reveal FGI-104 antiviral activity. 
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outcome.  
 
FGI-104 demonstrates efficacy in vivo  
 
Although the broad-spectrum antiviral activity 
observed above was compelling, we 
considered that these results were confined to 
cell-based assay systems. We sought to 
overcome this limitation using in vivo assays 
but a lack of relevant animal-based systems 
precluded investigation of HCV, HIV and most 
of the other virus types of relevance to FGI-
104. Therefore, we focused on animal models 
of Ebola hemorrhagic fever. Specifically, 
mouse-adapted Ebola provided a means to 
interrogate the antiviral properties of FGI-104 
in vivo [28]. For these studies, mice were 
infected with Ebola and then treated daily with 
Figure 4. FGI-104 inhibition of PRRS virus. Marc-145 cells were infected with PRRSV virus (23983) for 72 
hours in the presence or absence of FGI-104, with vehicle treated samples providing a negative control.  
Plaque formation was assessed visually (A) and the number of plaques quantified to determine the % 
reduction by FGI-104 (B). 
 
Development of a novel broad-spectrum antiviral 
Am J Transl Res 2009;1(1):87-98 95 
FGI-104. A vehicle-treated group provided a 
matched negative control. Unfortunately, no 
positive control was available since no other 
therapeutic was available that can block 
Ebola-mediated pathophysiology.   Consistent 
with its efficacy in cell-based assays, FGI-104 
treatment prevented Ebola-mediated killing of 
infected animals. Whereas vehicle-treated 
animals succumbed within 7 days post-
infection, all mice treated with FGI-104 
demonstrated lived longer and all animals in 
the FGI-104 group survived (Figure 6). Ebola is 
relatively immunogenic and those animals that 
survive beyond 10 days post-infection 
generally acquire immunity to subsequent 
challenge. As an additional control, the 
surviving animals were re-challenged after 14 
days with Ebola and each survived, thus 
verifying that the animals had encountered 
Ebola but that FGI-104 spared these animals 
from an otherwise lethal infection. 
 
Discussion 
 
The major finding of our present study is the 
identification of a small molecule inhibitor of 
viral disease, with the potential for broad-
spectrum application to a wide array of 
unrelated virus types.  We also demonstrate 
that FGI-104 demonstrates antiviral efficacy at 
concentrations that are substantially lower 
than those required to initiate host cell toxicity, 
thus suggestive of a safe therapeutic window. 
Consistent with this finding, FGI-104 treatment 
was sufficient to prevent lethal infections with 
Ebola virus in animals-based models.  
 
The fundamental principle underlying our 
investigation centers upon the concept of host-
oriented therapeutics for infectious disease. 
Host-oriented therapeutics seeks to identify 
host-based mechanisms and therapeutics that 
deny viral pathogens the ability to cause 
disease.  The advantages of a successful host-
oriented therapeutic could be many-fold.  For 
example, it is generally understood that many 
different viruses are completely dependent 
upon a relative small subset of host targets 
and mechanisms. This fact presents an 
opportunity to identify host targets that are 
shared among different virus types and 
inhibition of these pathways could have broad-
spectrum application for prevention or therapy. 
By definition, host-oriented therapeutics 
impact the host and not a viral target. Unlike 
their virally-encoded counterparts, host-
encoded targets are genetically stable and 
moreover, these targets are fundamental for 
the virus and direct selective pressure is not 
placed upon the viral pathogen.  Thus, we 
anticipate that a successful host-oriented 
therapeutic will demonstrate reduced 
Figure 5. Broad-spectrum inhibition of biothreat viruses by FGI-104.  The antiviral activity of FGI-104 was 
assessed using cell-based assays of Ebola hemorrhagic fever (EBOV) (A) or cowpox (B) viruses.  Please note 
these two particular findings were representative of the breadth of viral inhibition (Ebola is an RNA virus 
whereas cowpox is a DNA virus) and that FGI-104 demonstrated antiviral activity even when using different 
types of readouts (Inhibition of virus-mediated killing of host cells or plaque-based readouts of viral titer). 
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susceptibility to viral resistance mechanisms 
that often thwart the efficacy of conventional 
virus-oriented therapeutics [32, 33].  
 
One novel aspect of our present study is the 
demonstration that FGI-104 can inhibit 
multiple and different viral pathogens. A 
practical example of the application of such a 
broad-spectrum application would center upon 
the treatment of a constellation of blood-borne 
pathogens.  The studies herein represented by 
the shared efficacy of FGI-104 when target a 
constellation of blood-borne viral pathogens 
(HBV, HCV, and HIV) provide a glimpse of the 
potential application of FGI-104 to treat or 
prevent viruses, which are often co-morbid 
within particular populations [29]. Successful 
development of this strategy could likewise 
apply to other pathogens such as 
simultaneous targeting of different pathogens 
responsible for respiratory infections (e.g., 
seasonal infection with influenza and RSV), 
sexually-transmitted diseases (Herpes and 
HIV) or other constellations of viral-mediated 
diseases. 
 
Our demonstration of efficacy against Ebola 
virus in vivo is particularly intriguing in light of 
the well-understood and extreme pathogenicity 
of Ebola and because Ebola represents an 
emerging pathogen potential biothreat agent 
[34, 35].  At the mechanistic level, Ebola has 
been shown to require TSG101 for its 
dissemination [36] and this understanding is 
consistent with the original strategy described 
herein, which predicted that FGI-104 would 
inhibit the interaction of TSG101 with its 
cognate viral ligands, i.e., ‘PTAP’ late domain 
sequence in the Ebola VP40.  Although future 
investigation will be required to test the 
hypothesis that FGI-104 directly inhibits 
TSG101, such knowledge could have far-
reaching implications since genetic-based 
analysis suggests that TSG101 provides an 
essential function for many different virus 
types.  However, we cannot preclude that FGI-
104 might also impact other pathways and 
additional investigation will be required to 
dissect further the mechanistic basis of FGI-
104 antiviral activity. 
 
In the course of investigation FGI-104, 
pharmacokinetics studies have revealed that 
the molecule is amenable to delivery via oral 
Figure 6. Antiviral efficacy of FGI-104 in animal-based models of Ebola infection. Shown is an assay of FGI-
104 efficacy in Mice following a lethal Ebola Challenge. C57Bl/6 mice were challenged with 1000 pfu of 
mouse adapted Ebola and treated  with 10 mg/kg/day of FGI-104. Overall survival was assessed, revealing 
the characteristic lethality of Ebola 7-8 days post-infection.  Whereas vehicle-treated controls succumbed as 
expected, at least one half of FGI-104-treated animals survived lethal challenge. 
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or intravenous route (data not shown). FGI-104 
is also well-tolerated, with LD50 values greater 
than 1 g/kg in mice (as compared with the 
efficacy observed herein at 10 mg/kg).  In light 
of the fact that cell-based assays indicated a 
much higher EC50 value for Ebola (10 M) 
than HBV or HCV, these findings suggest a 
high relative safety margin for FGI-104. Thus, 
the work described with a handful of blood-
borne or biothreat agents could have a much 
more far-reaching impact for combating viral 
diseases. 
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